Price T Rowe Associates Inc Edgewise Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 23,808 shares of EWTX stock, worth $706,145. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,808
Previous 23,086
3.13%
Holding current value
$706,145
Previous $416,000
52.88%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding EWTX
# of Institutions
191Shares Held
100MCall Options Held
2.17MPut Options Held
410K-
Orbimed Advisors LLC San Diego, CA15MShares$446 Million9.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$264 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$178 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$173 Million1.67% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$165 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.87B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...